BCEL vs. IMNN, EDSA, RDHL, MIRA, KPRX, AVTX, HUGE, PIRS, ELAB, and KTRA
Should you be buying Atreca stock or one of its competitors? The main competitors of Atreca include Imunon (IMNN), Edesa Biotech (EDSA), RedHill Biopharma (RDHL), MIRA Pharmaceuticals (MIRA), Kiora Pharmaceuticals (KPRX), Avalo Therapeutics (AVTX), FSD Pharma (HUGE), Pieris Pharmaceuticals (PIRS), Elevai Labs (ELAB), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Imunon (NASDAQ:IMNN) and Atreca (NASDAQ:BCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
In the previous week, Imunon had 2 more articles in the media than Atreca. MarketBeat recorded 2 mentions for Imunon and 0 mentions for Atreca. Atreca's average media sentiment score of 1.88 beat Imunon's score of 0.00 indicating that Imunon is being referred to more favorably in the media.
4.5% of Imunon shares are held by institutional investors. Comparatively, 37.5% of Atreca shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 11.3% of Atreca shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Imunon currently has a consensus price target of $12.00, suggesting a potential upside of 733.33%. Given Atreca's stronger consensus rating and higher probable upside, research analysts plainly believe Imunon is more favorable than Atreca.
Imunon has higher revenue and earnings than Atreca. Imunon is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.
Atreca's return on equity of -122.68% beat Imunon's return on equity.
Atreca received 86 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 67.86% of users gave Atreca an outperform vote.
Imunon has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Atreca has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
Summary
Imunon beats Atreca on 11 of the 16 factors compared between the two stocks.
Get Atreca News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
